賽生藥業(06600.HK)擬全球發售1.16億股 引入IDG等多家基石
格隆匯 2 月 19日丨賽生藥業(06600.HK)發佈公吿，公司擬全球發售約1.16億股股份，其中香港發售股份1159.9萬股，國際發售股份約1.04億股，另有15%超額配股權；2021年2月19日至2月24日招股，預期定價日為2月24日；發售價每股發售股份17.20港元-18.80港元，每手買賣單位500股，入場費約9495港元；摩根士丹利、中金公司及瑞信為聯席保薦人，預期股份將於2021年3月3日於聯交所主板掛牌上市。
公司是一家擁有產品開發和商業化集成平台的生物製藥公司。公司在戰略上專注於中國一些最大且發展迅速的存在重大未滿足醫療需求的治療領域，主要包括腫瘤及重症感染。憑藉公司的集成平台，公司力圖在重點治療領域開發優質上市產品(包括公司的自有產品日達仙)及在研藥物的組合並對其進行商業化。
公司已與基石投資者訂立基石投資協議，據此，基石投資者已同意在若干條件的規限下按發售價認購總金額約10.366億港元可購買的相關數目的發售股份。基於發售價每股發售股份18.00港元(即發售價中位數)，基石投資者將予認購的股份總數將為5758.65萬股，佔發售股份的約49.65%及緊隨全球發售完成後已發行股本總額的約8.50%(假設超額配售權未獲行使)。基石投資者包括上藥國際供應鏈有限公司(上海醫藥集團間接全資附屬公司)、Daguan International Limited、中郵創業國際資產管理有限公司、Ding Asset Ltd、Bradbury Global Opportunity Fund SP、祥輝投資有限公司、IDG Capital Investment 2020 Limited、大眾(香港)國際有限公司(上海大眾(01635.HK/600635.SH)全資附屬及海外投資控股公司)、太平資產管理(香港)有限公司、富喬鑫資本(香港)有限公司、及黃展雄先生。
假設發售價為每股股份18.00港元(即發售價中位數)，公司估計將收取的全球發售所得款項淨額約19.504億港元(假設超額配售權未獲行使)。其中，所得款項淨額約30.0%將用於投資中國或其他全球市場的潛在藥物收購目標併為新候選藥物的授權引入提供資金；約28.0%將用於償還現有債務；約26.0%將用於為公司臨牀階段候選產品的開發及商業化提供資金；約10.0%將投入用於招聘、擴大銷售與營銷網絡以及商業及開發基礎設施；約6.0%將用於為公司上市產品組合進行額外臨牀應用的持續臨牀研究提供資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
